Ellocy Wart Remover

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Plantar warts are specifically identified by their location on the bottom of the foot, tenderness upon pressure, and the disruption of the normal footprint pattern.

There are no teratogenic or nonteratogenic effects mentioned associated with this drug.

Dosage and Administration

Healthcare professionals are advised to instruct patients to wash the affected area thoroughly before application. After cleansing, the area should be dried completely to ensure optimal adherence of the medication.

The recommended application frequency is twice daily, with each application consisting of 2 to 3 doses. Treatment should be continued for a duration of 5 to 7 days to achieve the desired therapeutic effect.

Contraindications

Use is contraindicated in the following situations:

Application on damaged skin, including cuts, abrasions, eczema, or sunburn, is prohibited due to the potential for increased irritation and adverse effects. Additionally, the use of this product is contraindicated in pregnant or breastfeeding individuals, as safety has not been established in these populations.

Warnings and Precautions

For external use only. This product is contraindicated for application on damaged skin, including areas with cuts, abrasions, eczema, or sunburn. Healthcare professionals should advise patients against use during pregnancy or while breastfeeding due to potential risks.

Patients should be instructed to discontinue use and contact their healthcare provider if they experience any irritation or signs of an allergic reaction. In cases where irritation persists, immediate medical attention is warranted to address any potential complications.

Side Effects

For external use only. Patients are advised to discontinue use if irritation or an allergic reaction occurs. It is recommended that individuals consult a healthcare professional if they are pregnant, breastfeeding, or have diabetes prior to use. No specific adverse reactions were reported in clinical trials or postmarketing experiences.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Ellocy Wart Remover (wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. It is essential to ensure that the medication is stored safely to prevent accidental ingestion or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should not use this medication. It is essential for women of childbearing potential to consult with their healthcare provider if they are pregnant or breastfeeding before initiating treatment. The potential risks associated with the use of this medication during pregnancy or lactation have not been established, and caution is advised to avoid any adverse fetal outcomes or effects on breastfeeding infants.

Lactation

Lactating mothers are advised against the use of this medication while breastfeeding. There is insufficient data regarding the excretion of the drug in human breast milk and its effects on breastfed infants. Therefore, it is recommended that lactating mothers consult their healthcare provider for guidance if they are pregnant or breastfeeding.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific details regarding overdosage for this product (SPL code 34088-5), healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdosage.

Recommended Actions In the event of an overdosage, it is essential to seek immediate medical attention. Healthcare providers should assess the patient's clinical status and consider the need for supportive care. Monitoring vital signs and providing symptomatic treatment may be necessary.

Potential Symptoms While specific symptoms of overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise. Symptoms may vary based on the pharmacological profile of the product and the individual patient's response.

Management Procedures Management of overdosage should be tailored to the individual case. Healthcare professionals are encouraged to consult established guidelines and protocols for the management of overdosage related to similar compounds. In cases where the specific antidote or treatment is known, it should be administered as appropriate.

In summary, due to the lack of specific overdosage information, healthcare professionals must rely on their clinical judgment and established medical protocols to manage any suspected cases effectively.

Nonclinical Toxicology

The use of this product is contraindicated in individuals who are pregnant or breastfeeding due to potential teratogenic effects. No non-teratogenic effects have been reported in the available data. Additionally, there is no further information provided regarding nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse. Patients should be instructed not to apply the product on damaged skin, including areas with cuts, abrasions, eczema, or sunburn, as this may exacerbate irritation or lead to adverse effects.

It is essential to inform patients that the product should not be used during pregnancy or while breastfeeding. They should be encouraged to consult with their healthcare provider if they are pregnant or breastfeeding before using the product.

Patients should be made aware that they must discontinue use if any irritation or allergic reaction occurs. In the event of irritation, they should be instructed to stop using the product immediately.

When using the product, patients should be cautioned to avoid contact with the eyes. If the product accidentally comes into contact with the eyes, they should flush the eyes with water for 15 minutes and seek medical attention if irritation persists.

Additionally, patients with diabetes should be advised to consult their healthcare provider before using the product to ensure it is safe for their specific health condition.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It should be stored at a temperature range of 20 to 25℃ (68 to 77℉). Care must be taken to protect the product from excessive heat, specifically temperatures exceeding 40℃ (104℉). Proper storage conditions are essential to maintain the integrity and efficacy of the product.

Additional Clinical Information

The medication is administered topically, with a recommended application frequency of two times a day, involving 2 to 3 applications during each session. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Ellocy Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)